Table 4.
Efficacy of ICIs in NSCLS with RET mutations.
| Reference | Characteristics | ORR, % | mPFS, months | mOS, months since start of ICI |
|---|---|---|---|---|
| Guisier F., et al. (47) | RET fusion (n=9) | 37.5 | 7.6 | NR (not reached) |
| Lee J., et al. (64) | RET fusion (n=13) | 7.7 | 2.1 | 12.4 |
| Mazieres J., et al. (31) | RET fusion (n=16) | 6 | 2.1 | 21.3 |
| Offin M., et al. (61) | RET fusion (n=16) | 0 | 3.4 | |
| Dudnik E., et al. (46) | RET fusion (n=4) | 0 | 3 | 14.9 |
| RET mutation (n=1) | 0 | 6.9 | 15.3 |
ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; ORR, overall response rate; mPFS, median progression-free survival; mOS, median overall survival.